ZYME Covered Call Strategy
ZYME (Zymeworks Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
ZYME (Zymeworks Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.81B, a beta of 1.19 versus the broader market, a 52-week range of 10.93-29.75, average daily share volume of 662K, a public-listing history dating back to 2017, approximately 299 full-time employees. These structural characteristics shape how ZYME stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.19 places ZYME roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a covered call on ZYME?
A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income.
Current ZYME snapshot
As of May 15, 2026, spot at $23.70, ATM IV 43.70%, IV rank 2.60%, expected move 12.53%. The covered call on ZYME below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this covered call structure on ZYME specifically: ZYME IV at 43.70% is on the cheap side of its 1-year range, which means a premium-selling ZYME covered call collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 12.53% (roughly $2.97 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ZYME expiries trade a higher absolute premium for lower per-day decay. Position sizing on ZYME should anchor to the underlying notional of $23.70 per share and to the trader's directional view on ZYME stock.
ZYME covered call setup
The ZYME covered call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ZYME near $23.70, the first option leg uses a $24.89 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ZYME chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ZYME shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $23.70 | long |
| Sell 1 | Call | $24.89 | N/A |
ZYME covered call risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium.
ZYME covered call payoff curve
Modeled P&L at expiration across a range of underlying prices for the covered call on ZYME. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use covered call on ZYME
Covered calls on ZYME are an income strategy run on existing ZYME stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
ZYME thesis for this covered call
The market-implied 1-standard-deviation range for ZYME extends from approximately $20.73 on the downside to $26.67 on the upside. A ZYME covered call collects premium on an existing long ZYME position, trading off upside above the short call strike for immediate income; the short strike selection should reflect the trader's view on whether ZYME will breach that level within the expiration window. Current ZYME IV rank near 2.60% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ZYME at 43.70%. As a Healthcare name, ZYME options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ZYME-specific events.
ZYME covered call positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ZYME positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ZYME alongside the broader basket even when ZYME-specific fundamentals are unchanged. Short-premium structures like a covered call on ZYME carry tail risk when realized volatility exceeds the implied move; review historical ZYME earnings reactions and macro stress periods before sizing. Always rebuild the position from current ZYME chain quotes before placing a trade.
Frequently asked questions
- What is a covered call on ZYME?
- A covered call on ZYME is the covered call strategy applied to ZYME (stock). The strategy is structurally neutral to slightly bullish: A covered call pairs long stock with a short out-of-the-money call, collecting premium and capping upside above the short strike in exchange for income. With ZYME stock trading near $23.70, the strikes shown on this page are snapped to the nearest listed ZYME chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ZYME covered call max profit and max loss calculated?
- Max profit equals short-strike minus cost basis plus premium times 100; max loss is cost basis minus premium (at zero). Breakeven is cost basis minus premium. For the ZYME covered call priced from the end-of-day chain at a 30-day expiry (ATM IV 43.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ZYME covered call?
- The breakeven for the ZYME covered call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ZYME market-implied 1-standard-deviation expected move is approximately 12.53%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a covered call on ZYME?
- Covered calls on ZYME are an income strategy run on existing ZYME stock positions; traders typically sell calls at 25-35 delta with 30-45 days to expiration to balance premium against upside cap.
- How does current ZYME implied volatility affect this covered call?
- ZYME ATM IV is at 43.70% with IV rank near 2.60%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.